L-DOPA-Induced Facilitation of Dopamine Release VIA Presynaptic β-Adrenoceptors in Striatal Slices from MPTP-Treated C57BL Mice: Evaluation of the Action of L-DOPA in Animal Model for Parkinsonism
L-3,4-Dihydroxyphenylalanine (DOPA) is the most effective therapeutic agent for Parkinson’s disease and is believed to act exclusively via its conversion to dopamine (DA). However, we proposed that DOPA itself may act as an endogenous neuroactive substance.1–3 To asses this proposal, we employed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-treated C57 black (BL) mice as a model for parkinsonism, and examined the effect of L-DOPA in this system by observing striatal slices from these animals.
KeywordsSubstantia Nigra Tissue Content Final Injection Striatal Slice Effective Therapeutic Agent
Unable to display preview. Download preview PDF.
- 4.N. Arai, K. Misugi, Y. Goshima, and Y. Misu, Evaluation of a 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C 57 black mouse model for parkinsonism, Brain Res., in press.Google Scholar